Curis, Inc. (CRIS)
| Market Cap | 2.09M -90.0% |
| Revenue (ttm) | 4.31M -62.2% |
| Net Income | -21.15M |
| EPS | -18.06 |
| Shares Out | 2.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 123,011 |
| Open | 1.110 |
| Previous Close | 1.090 |
| Day's Range | 1.000 - 1.128 |
| 52-Week Range | 1.000 - 35.638 |
| Beta | 3.00 |
| Analysts | Strong Buy |
| Price Target | 42.67 (+4,167.0%) |
| Earnings Date | Nov 5, 2026 |
About CRIS
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refra... [Read more]
Financial Performance
In 2025, Curis's revenue was $9.44 million, a decrease of -13.43% compared to the previous year's $10.91 million. Losses were -$7.58 million, -82.53% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CRIS stock is "Strong Buy." The 12-month stock price target is $42.67, which is an increase of 4,167.00% from the latest price.
News
Curis announces pricing of $5.6M public offering
Curis (CRIS) announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the…
Curis Quarterly report: Q2 2026
Curis has published its Q2 2026 quarterly earnings report on August 14, 2026.
Curis, Inc. Announces Pricing of $5.6 Million Public Offering
LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and F...
Curis files to sell 3.73M shares of common stock, warrants
A.G.P./Alliance Global Partners and Laidlaw & Company are acting as placement agents.
Curis Registration statement: Registration filing
Curis filed a registration statement on August 10, 2026, providing details about a securities offering with the SEC.
Curis doses first five patients in TakeAim CLL study
Curis (CRIS) announced an enrollment milestone in its TakeAim CLL study in patients with Chronic Lymphocytic Leukemia, or CLL. Curis has achieved the goal of dosing the first five patients…
Curis Doses First Five Patients in TakeAim CLL Study
LEXINGTON, Mass., July 30, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and F...
Curis price target raised to $43 from $17 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Curis (CRIS) to $43 from $17 and keeps a Buy rating on the shares. The firm added a valuation for emavusertib in…
Curis Transcript: Study update
Updated data show emavusertib plus ibrutinib achieves high response rates in both BTKI-naive and BTKI-experienced PCNSL patients, exceeding historical controls. Regulatory discussions support accelerated approval, and expansion into CLL and other NHL subtypes is underway.
Curis Press release: Study update
Curis issued a press release on July 22, 2026, disclosing material business information to investors.
Curis Slides: Study update
Curis has posted slides in relation to its latest quarterly earnings report, which was published on July 22, 2026.
Curis to report clinical data in the TakeAim Lymphoma study
Curis (CRIS) announced that it will host a webcast on Wednesday, July 22 to discuss positive updated clinical data in the TakeAim Lymphoma study, its ongoing registrational study in Primary…
Curis Announces Positive Emavusertib Update
Updated Clinical Data in PCNSL Increased Guidance on Year-End Data in CLL Company to Host Webcast at 8:30 a.m. ET LEXINGTON, Mass.
Curis Slides: Corporate presentation
Curis has posted slides in relation to its latest quarterly earnings report, which was published on July 15, 2026.
Curis consents first six patients in TakeAim CLL study
On June 26, Curis (CRIS) announced that eleven clinical sites had opened for enrollment in the TakeAim CLL study. Curis is announcing that it has consented the first six patients…
Curis Consents First Six Patients in TakeAim CLL Study
LEXINGTON, Mass., July 6, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FL...
Curis trading halted, news pending
19:50 EDT Curis (CRIS) trading halted, news pending
Curis announces eleven active clinical sites in TakeAim CLL study
Curis (CRIS) announced that eleven clinical sites have been initiated and are now open for patient enrollment in its Phase 2 TakeAim CLL study evaluating emavusertib in combination with zanubrutinib…
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
Eleven sites open for patient enrollment in TakeAim CLL combination study with zanubrutinib; Company reaffirms guidance for dosing of initial five patients by end of July 2026 with data expected Decem...
Curis Transcript: EGM 2026
Stockholders approved both a reverse stock split and the option to adjourn the meeting if needed. No questions were raised, and final results will be filed in a Form 8-K within four business days.
Curis Proxy statement: Proxy filing
Curis filed a proxy statement on June 5, 2026, providing details for shareholder voting and corporate governance matters.
Curis Slides: Corporate presentation
Curis has posted slides in relation to its latest quarterly earnings report, which was published on June 5, 2026.
Curis Proxy statement: Proxy filing
Curis filed a proxy statement on May 22, 2026, providing details for shareholder voting and corporate governance matters.
Curis Transcript: AGM 2026
The meeting covered five key proposals, including director elections, executive compensation, auditor ratification, and an increase in authorized shares, all of which were approved by majority vote. Voting procedures and risks related to forward-looking statements were also addressed.
Curis reports Q1 EPS ($1.25), consensus (29c)
Reports Q1 revenue $0, consensus $1.86M. As of March 31 Curis’s (CRIS) cash and cash equivalents totaled $15.0M, and the Company had approximately 40.0 million shares of common stock outstanding.